Top Links
Journal of Hematology and Blood Disorders
ISSN: 2455-7641
The Impact of Repeated Hb A2 Measurements on β-Thalassemia Trait Diagnosis
Copyright: © 2016 Al-Jafar H. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at Pubmed, Google Scholar
Introduction: Hemoglobin A2 (Hb A2) is a minor component of the hemoglobin present in normal adult red blood cells, accounting for 1.5-3.5% of the total hemoglobin in healthy individuals. The Hb A2 level is the most significant parameter to identify β-thalassemia carriers. We aimed to study the effect of repeated measurements of Hb A2 levels on β-thalassemia trait diagnosis.
Methods: Repeated HPLC tests were conducted for 107 patient samples. Results were categorized into variant interval ranges (VIRs); each interval has 0.25% deviation from the repeated test. The following six VIRs were created: 0.25, 0.50, 0.75, 1.00, 1.25, and 1.50%. HPLC results were interpreted in correlation with red blood cell indices, and serum ferritin. Serum ferritin was available for 76 patients from medical records.
Results: All samples showed different degrees of variation between repeated test results. The variations ranged from 0.25% VIR in 51 (47%) of the repeated test results and 1.5% VIR in 7 (7%).
Conclusion: The normal range Hb A2 levels are very narrow window. Repeated HPLC results for samples showed degrees of variation that could alter β-thalassemia trait diagnosis. Alert technical work and careful clinical interpretation are mandatory to avoid wrong diagnosis related to Hb A2 level in β-thalassemia trait and other related hemoglobin disorders. This comparative study on repeated HPLC for Hb A2 levels has great importance to avoid either false negative or false positive results.
Keywords: Hemoglobinopathy; Standardization; HPLC; Thalassemia minor; Quality control
Hemoglobin A2 (Hb A2) level is the most significant parameter in the identification of β-thalassemia carriers. A small percentage of hemoglobin A2 is present in normal adult red blood cells (RBC), accounting for about 1.5-3.5% of the total Hb in healthy individuals [1]. Several research studies have confirmed typical increase of Hb A2 in β thalassemia carriers, thus providing evidence for the use of Hb A2 as a diagnostic tool for such condition [2]. From that time on, β thalassemia carriers have been diagnosed by their Hb A2 levels, which are usually above normal average. Other evidence, collected through the United Kingdom National External Quality Assessment Service (NEQAS) survey showed that some High Performance Liquid Chromatography (HPLC) methods are not well aligned with those of other systems, with a positive bias of up to 0.5% in Hb A2 results [3]. Iron deficiency could interfere with the diagnosis of β-thalassemia trait [4]. In patients with the β-thalassemia trait, iron level could be elevated and iron-depleted β-thalassemia carriers are found to have no significant reduction in Hb A2 level, although other studies reported low Hb A2 in iron deficiency anemia [5,6]. Moreover, reduced Hb A2 levels can be detected in the presence of α-thalassemia mutations, probably due to preferential binding of the α-chains with the β rather than with their δ counterparts. This is clearly seen in hemoglobin H disease (Hb H), where Hb A2 can drop to less than 1% [7]. Hb A2 levels could also be affected by congenital or acquired factors (Figure 1). The Hb A2 variations detected by repeated HPLC tests in this study could potentially influence the diagnosis of the β-thalassemia trait and another hemoglobinopathies. Therefore, this study highlights the impact of such variations on Hb A2 level quality control determined by HPLC testing.
A retrospective study was conducted to assess the variation between repeated HPLC results for the same sample. In our medical records, 107 patients were found to have repeated HPLC tests between 2010 and 2015 without known the reasons why the test was repeated, most likely it were repeated without checking the availability of the results in the records. HPLC analysis was performed using the Waters Corporation machine model 2487 Dual λ Absorbance Detector. From available records, samples that were repeat tested by HPLC and had high Hb A2 levels were included in this study. Samples with another hemoglobinopathy such as S, D, G, E, thalassemia major, or thalassemia intermedia were excluded. HPLC results were interpreted in correlation with red blood cell indices and serum ferritin levels. All the tested samples performed on same machine throughout this period. Each sample was repeated only one time but not on the same day. The variation interval ranges were vary between few days and several months. Serum ferritin was available in our data for 76 patients but it was not done at the same time as HPLC. It was included to give a useful available relevant data.
Repeated HPLC measurements revealed variations in Hb A2 levels (Table 1). These variations were categorised into variation interval ranges (VIRs); each VIR spanned 0.25%. Six VIRs were created 0.25, 0.50, 0.75, 1.00, 1.25, and 1.50%. Variations were detected in all the 107 samples had repeated HPLC tests. Analysis of the results of the 107 repeat tested samples revealed that 51 (47%) samples were in the 0.25% VIR; 28 (26%) samples were in the 0.5% VIR; 14 (13%) samples were in the 0.75% VIR; 5 (5%) samples were in the 1.00% VIR; 2 (2%) samples were in the 1.25% VIR; and 7 (7%) samples were in the 1.5% VIR. Serum ferritin level were available for 76 patients. Of these, 63 patients had normal serum ferritin levels; 2 patients had high serum ferritin; and 11 patients had low serum ferritin. After repeated testing, Hb A2 were corrected from normal level to high level for 2 samples according to high RBC, high Hb, low MCV and low MCH from normal level to high level for 2 samples (Table 2). The Hb A2 VIRs for all 107 samples were correlated to their RBC indices, Hb levels, and serum ferritin levels according to the hematology reference values based on age and gender (Table 3).
An elevated Hb A2 determined by the HPLC test, normal or high serum ferritin, microcytic hypochromic features, high RBC count, and low to normal total hemoglobin, are parameters to determine β-thalassemia trait diagnosis. Hb A2 plays an integral role in identifying the carrier status of a subject. The range for considering Hb A2 levels as normal is very narrow; therefore, a slight increase or decrease in the Hb A2 level could change the diagnosis from being considered positive for the β-thalassemia trait to normal and vice versa. The repeated HPLC tests show variation differences according to VIRs which could change the diagnosis (Figure 2).
For two patients, the first HPLC results showed normal Hb A2, which was in contradiction with the other parameters. However, when the test was repeated, the Hb A2 became higher than normal, which was consistent with β-thalassemia trait (Table 2). These results highlight the importance of correlating the Hb A2 level with other parameters before assigning a final diagnosis. The VIRs for Hb A2 levels were compared with RBC indices after sorting the samples based on age and gender, which confirmed the correlation between Hb A2 levels and RBC indices (Table 3).
Serum ferritin was available in our records for 76 patients but it was not done at the same time as HPLC. As expected, serum ferritin level was within the normal reference range in 63 patients. The serum ferritin level was high (520–824 μg/L) in only 2 patients. Depletion of iron stores was found in 11 patients, Four of these patients were males, with serum ferritin ranged between 10.8 and 17.1 μg/L; and 7 were females with a serum ferritin between 3.5 and 10.6 μg/L. Interestingly, all patients with low serum ferritin levels, had higher than normal Hb A2 levels when the HPLC was repeated, and the Hb A2 stayed greater than normal. Therefore, the diagnosis of β-thalassemia trait was not altered. This study showed no effect to the low serum ferritin level on Hb A2 level because with low serum ferritin the RBC count usually drop below the normal range, but the RBC count was high, in consistent to β-thalassemia trait rather than iron deficiency anemia. It is important finding although 11 samples with low serum ferritin and high Hb A2 and high RBC count is not large enough number to make conclusion about iron deficiency and its effect on the HbA2 level a further study needed for this significant results. This is an important finding because some other studies showed that low serum ferritin was thought to reduce Hb A2 level to normal or below normal in patients with β-thalassemia trait [8,9]. Serum ferritin level in patients with the β-thalassemia trait could be high [10]; our results revealed 2 patients with elevated serum ferritin levels without receiving blood transfusion. It is important to be aware of any interference that may falsely alter Hb A2 levels, leading to false positive (high) or false negative (low) Hb A2 level result, which may result in inappropriate diagnosis or management [11]. For example, as reported in the literature false negative Hb A2 could be caused by an iron deficiency or concurrent inheritance of the α-thalassemia trait [6]. Therefore, the quantification of Hb A2 levels has to be with high accuracy [12]. Many factors such as the lack of awareness among working technologists and clinical pathologists, or inadequate facilities, may result in imprecise outcomes and interpretations [13]. Another important finding in this study is that the repeated Hb A2 test results of 7 patients (7%) showed a difference of 1.5% from their first test results, whereas Hb A2 variation is only, up to 0.5% has been reported in literature [14]. This relatively large difference between the initial and repeated results of Hb A2 levels which may affect result in the interpretation, if the diagnosis is made solely based on HPLC results only. Equipment calibration, regular maintenance, test validation and the laboratory quality control are necessary to ensure high and accurate performance. Equivocal borderline high Hb A2 results warrant repeat testing using other modalities and/or genetic tests of the globin genes. There are a few cases of symptomatic refractory microcytic hypochromic anemia with borderline, normal, or reduced Hb A2 levels. These cases should be investigated for the presence of α-thalassemia or its co-inheritance with β-thalassemia gene [15], or silent β-thalassemia trait [16]. This study need to be repeated as a prospective study to confirm the findings with molecular biology techniques which couldn’t be done in this retrospective study.
The normal range for Hb A2 is very narrow. Small changes in Hb A2 levels can result in incorrect diagnosis. In this study the low serum ferritin did not decrease the Hb A2 to a normal level. Proper machine maintenance, standardized reagents, adequate training of HPLC testing for technologists and interpretive aspects from pathologists and physicians are crucial to make accurate diagnosis. HPLC result interpretation must be done in correlation with family study, RBC parameters, serum ferritin levels, and blood film morphology. High degree of suspicion helps to identify possible false positive or false negative results. Equivocal or inconclusive Hb A2 results should be investigated further by other methods such as DNA analysis.
We are grateful for the hematology laboratory team in hematology clinical laboratories in Amiri hospital for their assistant in this research work.
β-Thal = β -Thalassemia; α-Thal = αThalassemia; IDA = Iron deficiency anemia; RBC = Red blood count; Hb = Hemoglobin; MCV = Mean corpuscular volume; MCH = Mean corpuscular Hemoglobin; SF = Serum ferritin Figure 1: Causes of different HbA2 levels with the hematology laboratory results comparison between β-Thal, α-Thal, IDA |
Figure 2: Number of the samples in each variant interval range |
HbA2 Variations intervals |
Count |
percentage |
Hb A Mean ± SD (96 - 98) |
HbA2 Mean ± SD (1.5 - 3.5) |
Hb F Mean ± SD <1 |
RBC (4.5 - 5.5) 10 12 /L |
Hb (130 -170) g/L |
MCV (83 - 101) fL |
MCH (27 - 32) pg |
0.25 |
51 |
47% |
92.86 ± 2.56 |
5.19 ± 0.67 |
3.30 ± 2.46 |
5.62 ± 0.59 |
110 ± 12.2 |
62.2 ± 4.00 |
19.6 ± 1.41 |
0.50 |
28 |
26% |
93.52 ± 2.48 |
5.12 ± 0.75 |
2.52 ± 3.00 |
5.59 ± 0.83 |
107 ± 13.1 |
60.9 ± 4.47 |
19.3 ± 1.66 |
0.75 |
14 |
13% |
93.24 ± 2.53 |
5.29 ± 0.62 |
2.58 ± 2.82 |
5.43 ± 0.90 |
106 ± 16.7 |
62.8 ± 4.04 |
19.6 ± 1.45 |
1.00 |
5 |
5% |
92.70 ± 3.49 |
5.11 ± 0.62 |
3.63 ± 3.73 |
5.29 ± 0.83 |
104 ± 12.5 |
63.6 ± 5.06 |
19.8 ± 1.72 |
1.25 |
2 |
2% |
90.54 ± 2.67 |
5.43 ± 0.54 |
5.38 ± 2.37 |
5.47 ± 0.43 |
100 ± 3.77 |
56.3 ± 2.28 |
18.5 ± 1.12 |
1.50 |
7 |
7% |
94.31 ± 2.13 |
4.53 ± 1.11 |
2.41 ± 1.58 |
5.14 ± 0.83 |
106 ± 15.7 |
64.8 ± 5.41 |
20.7 ± 1.85 |
Table 1: Hb A2 variation intervals range |
No |
Gender |
HbA2 variations |
Repeated |
Hb A (96 - 98%) |
HbA2 (1.5 - 3.5%) |
Hb F <1% |
RBC (4.5 - 5.5) 10 12 /L |
Hb (130 -170) g/L |
MCV (83 - 101) fL |
MCH (27 - 32) pg |
Ferritin (23 - 336) ng/mL |
1 |
M |
2.64 |
1st |
97.07 |
2.7 |
<1 |
5.32 |
102 |
60 |
19 |
16.3 |
2nd |
94.10 |
5.4 |
<1 |
5.29 |
99 |
58 |
19 |
37.6 |
|||
2 |
M |
2.27 |
1st |
98.00 |
2.4 |
- |
5.74 |
125 |
68 |
22 |
84.9 |
2nd |
90.73 |
4.7 |
4.60 |
4.99 |
105 |
66 |
21 |
||||
Table 2: Hb A2 level before and after repetition in correlation to RBC indices and serum ferritin level |
HbA2 AIR |
Gender |
Age |
N |
Hb A (96 - 98) |
HbA2 (1.5 - 3.5) |
Hb F <1 |
RBC (4.5 - 5.5) 10 12 /L |
Hb (130 -170) g/L |
MCV (83 - 101) fL |
MCH (27 - 32) pg |
Ferritin (23 - 336) ng/mL |
0.25 |
F |
1 - 16 |
11 |
91.86 ± 2.65 |
5.17 ± 0.49 |
3.87 ± 2.63 |
5.59 ± 0.50 |
106 ± 10.0 |
60.5 ± 2.52 |
19.0 ± 1.00 |
22 ± 16 |
0.25 |
18 - 82 |
17 |
93.08 ± 2.29 |
5.26 ± 0.76 |
2.77 ± 1.68 |
5.33 ± 0.50 |
107 ± 10.0 |
63.6± 4.38 |
20.2± 1.29 |
29 ± 23 |
|
0.25 |
M |
1 - 16 |
9 |
91.31 ± 2.88 |
5.54 ± 0.55 |
4.33 ± 3.42 |
5.78 ± 0.39 |
106 ± 9.0 |
59.2 ± 2.35 |
18.3 ± 1.02 |
44 ± 24 |
0.25 |
19 - 77 |
14 |
94.06 ± 2.14 |
4.87 ± 0.57 |
3.33 ± 2.75 |
5.96 ± 0.67 |
120 ± 14.0 |
63.7 ± 3.59 |
20.2± 1.23 |
129 ± 145 |
|
0.50 |
F |
3 - 14 |
8 |
92.23 ± 2.53 |
5.54 ± 0.86 |
3.13 ± 2.66 |
5.69 ± 0.58 |
104 ± 9.5 |
58.5 ± 2.16 |
18.3 ± 1.00 |
48 ± 46 |
0.50 |
18 - 69 |
12 |
94.59 ± 1.07 |
4.79 ± 0.50 |
1.26 ± 1.00 |
5.26 ± 0.70 |
105 ± 13.0 |
63.2 ± 5.12 |
20.2 ± 1.93 |
122 ± 236 |
|
0.50 |
M |
1 - 15 |
6 |
93.15 ± 3.34 |
5.23 ± 0.69 |
3.70 ± 4.94 |
5.85 ± 1.14 |
111 ± 15.5 |
60.4 ± 4.32 |
19.2 ± 1.33 |
43 ± 4 |
0.50 |
63 |
2 |
94.69 ± 0.65 |
4.62 ± 0.17 |
1.06 ± 0.60 |
6.11 ± 0.34 |
117 ± 8.3 |
62.5 ± 1.12 |
19.2 ± 0.43 |
103 ± 53 |
|
0.75 |
F |
13 - 16 |
3 |
94.21 ± 0.59 |
5.28 ± 0.56 |
0.69 ± 0.28 |
5.56 ± 0.89 |
106 ± 19.7 |
60.6 ± 3.77 |
19.0 ± 1.41 |
16 ± 12 |
0.75 |
22 - 45 |
6 |
92.39 ± 3.26 |
5.39 ± 0.49 |
4.41 ± 3.74 |
4.75 ± 0.55 |
98 ± 12.5 |
66.0± 3.44 |
20.6 ± 1.44 |
769 ± 893 |
|
0.75 |
M |
4 - 14 |
3 |
92.26 ± 2.25 |
5.51 ± 0.73 |
3.25 ± 0.67 |
5.90 ± 0.34 |
111 ± 7.1 |
60.2 ± 2.27 |
19.0 ±1.0 |
31 |
0.75 |
39 - 58 |
2 |
94.90 ± 0.74 |
4.81 ± 0.59 |
0.46 ± 0.09 |
6.33 ± 0.80 |
121 ± 15.3 |
62.0 ± 1.67 |
19.2 ± 1.0 |
99 ± 23 |
|
1.00 |
F |
10 - 16 |
2 |
93.81 ± 1.73 |
5.20 ± 0.59 |
3.87 ± 0.00 |
5.62 ± 0.20 |
105 ± 2.9 |
60.5 ± 1.12 |
18.7 ± 0.43 |
12 |
1.00 |
22 - 30 |
2 |
94.54 ± 1.07 |
5.07 ± 0.70 |
0.52 ± 0.37 |
4.65 ± 0.99 |
101 ± 19.3 |
69.2 ± 2.86 |
21.7 ± 0.83 |
458 ± 317 |
|
1.00 |
M |
1 |
1 |
86.83 ± 2.97 |
5.00 ± 0.44 |
8.18 ± 2.53 |
5.91 ± 0.15 |
106 ± 2.0 |
58.5 ± 0.50 |
18.0 ± 0.00 |
13 |
1.25 |
M |
1 - 6 |
2 |
90.54 ± 2.67 |
5.43 ± 0.54 |
5.38 ± 2.37 |
5.47 ± 0.43 |
100 ± 3.77 |
56.2 ± 2.28 |
18.5 ± 1.12 |
32 ± 3.3 |
1.50 |
F |
23 - 56 |
3 |
94.54 ± 1.67 |
4.58 ± 1.08 |
2.16 ± 1.50 |
4.57 ± 0.70 |
95 ± 11.0 |
66.0 ± 6.0 |
21.0 ± 2.00 |
235 ± 24 |
1.50 |
M |
1 |
1 |
95.59 ± 1.49 |
4.06 ± 1.32 |
<1 |
5.31 ± 0.02 |
101 ± 1.50 |
59.0 ± 1.0 |
19.0 ± 0.00 |
38 |
1.50 |
49 - 57 |
3 |
93.63 ± 2.54 |
4.59 ± 1.05 |
2.56 ± 1.60 |
5.82 ± 0.50 |
121 ± 11.0 |
65.0 ± 4.0 |
21.0 ± 2.00 |
100 ± 15 |
|
Table 3: Hb A2 variations in correlation with RBC indices, hemoglobin and serum ferritin according to hematology reference values in different age and gender |